|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's Range||7.69 - 7.80|
|52 Week Range||3.47 - 21.27|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 02, 2022 - Nov 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. QDEL, LNTH and TGTX are well-poised to gain from the favorable factors.
QuidelOrtho, Lantheus and TG Therapeutics are part of Zacks Industry Outlook article.
TG Therapeutics (TGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.